HCPCS C1781 is officially defined as "Mesh (implantable)." HCPCS C1781 is referenced in 8 tracked payer policy changes from Arkansas Blue Cross Blue Shield, Anthem BCBS, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS C1781 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Arkansas Blue Cross and Blue Shield has published a new payment policy for mastectomy and breast reconstruction procedures under Arkansas Act 561, effective July 15, 2026. The policy requires manual review for specific surgical procedures and mandates reimbursement at 100% or greater of acquisition cost for required supplies, with providers needing to submit itemized invoices for mesh and nerve graft materials.
Effective April 1, 2026, Anthem Blue Cross will no longer reimburse separately for blood product splitting, pooling, and thawing services, as well as professional/technical components and supplies for blood product administration and routine ECG when billed with facility or room fees. Facilities must bundle these services into primary service or facility fee reimbursement. Several new codes have been added to the related coding section for reference.
Effective April 1, 2026, Anthem Blue Cross Blue Shield (Georgia) is bundling blood product splitting, pooling, and thawing services into facility fees with no separate reimbursement allowed. Additionally, professional/technical components and supplies for blood product administration and routine ECG will not be separately reimbursable when billed with room/facility fees or procedures. Specific HCPCS codes have been added to the related coding section.
Effective April 1, 2026, Anthem is bundling blood product services (splitting, pooling, thawing, and administration) into facility fees for inpatient settings in Ohio. Facilities can no longer bill these services separately on the same date of service as a room/facility fee or procedure. Six new HCPCS codes have been added to the related coding section.
Aetna's Clinical Policy Bulletin 0185 on breast reconstructive surgery, last reviewed 10/20/2026, sets out the reconstructive procedures and acellular dermal matrices Aetna considers medically necessary when criteria are met, such as after a medically necessary mastectomy or lumpectomy that results in a significant deformity. It lists procedures considered experimental, investigational or unproven, and it states that breast reconstructive surgery is cosmetic for all other indications not listed. The policy also lists the CPT, HCPCS and ICD-10 codes it covers and the codes it does not cover.
Aetna considers breast reconstructive surgery medically necessary after a medically necessary mastectomy or lumpectomy that results in a significant deformity. Medically necessary procedures include autologous fat grafting, tissue expander use, breast prosthesis implantation, mastopexy, nerve coaptation for improvement of sensation in breast reconstruction for cancer, and flap reconstructions such as DIEP, TRAM, latissimus dorsi, superior gluteal artery perforator and profunda artery perforator flaps. Alloderm, Alloderm-RTU, Cortiva, DermACELL, DermaMatrix, FlexHD, Strattice and SurgiMend are medically necessary acellular dermal matrices, while Artia, the Biodesign Nipple Reconstruction Cylinder, SimpliDerm for breast reconstruction, the body lift perforator flap technique, intraoperative hypothermia in breast reconstruction, venous super-charging and 3D volumetric imaging are considered experimental, investigational or unproven. Aetna considers breast reconstructive surgery cosmetic for all other indications not listed in the policy, and many Aetna plans specify that certain surgeries, such as post-mastectomy breast reconstruction, are not considered cosmetic.
Cranial remodeling bands or helmets are considered medically necessary orthoses for moderate-to-severe positional head deformities associated with premature birth, restrictive intra-uterine positioning, cervical abnormalities, birth trauma, torticollis and sleeping positions in children, when banding starts at 3 to 12 months of age, a 2-month trial of repositioning has failed and is judged unlikely to work, and anthropometric data or medical notes document the asymmetry. Banding after surgery for synostotic plagiocephaly is considered medically necessary to correct continued asymmetry, and a trial of conservative therapy is not needed in that case, while a second band or helmet is medically necessary only under the listed conditions and bands are contraindicated after 2 years of age or in unshunted or uncontrolled hydrocephalus. Use for persons who do not meet these criteria is considered cosmetic, and banding without surgery for synostotic plagiocephaly, pre-operative molding helmet therapy for sagittal craniosynostosis, banding for calcified cephalohematoma, and polycaprolactone mesh in pediatric cranial vault remodeling are considered experimental, investigational or unproven.
Aetna considers dynamic MRI in persons with complex organ prolapse to supplement the physical examination, laparoscopic suture rectopexy for rectal prolapse, Le Fort colpocleisis for severe utero-vaginal prolapse in elderly and chronically ill persons who no longer desire coital function, sacrocolpopexy for vaginal apical prolapse repair, and tension-free vaginal tape for pelvic organ prolapse complicated by stress urinary incontinence medically necessary. Aetna considers biodegradable cog threads, biologic grafts for vaginal apical prolapse, combined laparoscopic-vaginal lateral suspension, pectopexy, laser therapy, transcutaneous electrical nerve stimulation, trans-vaginal absorbable meshes or biological grafts, vNOTES presacral-uterosacral hysteropexy, vNOTES uterosacral ligament suspension, vaginal tactile imaging, and genetic testing experimental, investigational, or unproven for pelvic organ prolapse. The covered CPT codes apply when the selection criteria are met, and specific CPT, HCPCS and ICD-10 codes are listed as not covered for the indications in the policy.
Watch C1781
Get one email when a payer policy names C1781, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for C1781
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for C1781 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.